Effect of statins on skeletal muscle: Exercise, myopathy, and muscle outcomes

Exercise and Sport Sciences Reviews

Volumn 40, Issue 4, 2012, Pages 188-194

  Parker, Beth A ^a,b,c   Thompson, Paul D ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HARTFORD   (United States)

Author keywords

aerobic capacity; cholesterol lowering medication; HMG CoA reductase inhibitor; muscle strength; myalgia; vitamin D

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXERCISE; HUMAN; MUSCLE DISEASE; SKELETAL MUSCLE;

ANIMALS; EXERCISE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SKELETAL; MUSCULAR DISEASES;

EID: 84866890172     PISSN: 00916331     EISSN: None     Source Type: Journal    
DOI: 10.1097/JES.0b013e31826c169e     Document Type: Article

References (35)

1. Bouitbir J, Charles AL, Rasseneur L, et al. Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J. Appl. Physiol. 2011; 111(5):1477-83.
2. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patientsVthe PRIMO study. Cardiovasc. Drugs Ther. 2005; 19(6):403-14.
3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279(20):1615-22.
4. Evans WJ, Meredith CN, Cannon JG, et al. Metabolic changes following eccentric exercise in trained and untrained men. J. Appl. Physiol. 1986; 61(5):1864-8.
5. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97.
6. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010; 210(2):337-43.
7. Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011; 215(1):23-9.
8. Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J. Clin. Invest. 2007; 117(12):3940-51.
9. Hubal MJ, Reich KA, De BA, et al. Transcriptional deficits in oxidative phosphorylation with statin myopathy. Muscle Nerve. 2011; 44(3):393-401.
10. Isackson PJ, Ochs-Balcom HM, Ma C, et al. Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS. Muscle Nerve. 2011; 44(4):531-8.
11. Kearns AK, Bilbie CL, Clarkson PM, et al. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis. 2008; 200(1):121-5.
12. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr. Opin. Lipidol. 2010; 21(4):324-8.
13. Liantonio A, Giannuzzi V, Cippone V, Camerino GM, Pierno S, Camerino DC. Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system. J. Pharmacol. Exp. Ther. 2007; 321(2):626-34.
14. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statinintolerant patients. N. Engl. J. Med. 2011; 365(24):2250-1.
15. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J. Am. Coll. Cardiol. 2007; 49(23):2231-7.
16. Meador BM, Huey KA. Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise. Muscle Nerve. 2011; 44(6):882-9.
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360(9326): 7-22.
18. Parker BA, Augeri AL, Capizzi JA, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am. J. Cardiol. 2012; 109(2): 282-7.
19. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 2002; 137(7):581-5.
20. PDR Staff. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002, p. 56.
21. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934): 1383-9.
22. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359(21):2195-207.
23. Ruano G, Thompson PD, Windemuth A, et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007; 36(3): 329-35.
24. Ruano G, Thompson PD, Windemuth A, et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics. 2005; 6(8):865-72.
25. Ruano G, Windemuth A, Wu AH, et al. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis. 2011; 218(2): 451-6.
26. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br. J. Clin. Pharmacol. 2004; 57(4):525-8.
27. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 2002; 346(7):539-40.
28. Thompson PD, Gadaleta PA, Yurgalevitch S, Cullinane E, Herbert PN. Effects of exercise and lovastatin on serum creatine kinase activity. Metabolism. 1991; 40(12):1333-6.
29. Thompson PD, Nugent AM, Herbert PN. Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors. JAMA. 1990; 264(23):2992.
30. Thompson PD, Parker BA, Clarkson PM, et al. A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Prev. Cardiol. 2010; 13(3):104-11.
31. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997; 46(10):1206-10.
32. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler. Thromb. Vasc. Biol. 2005; 25(12):2560-6.
33. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet. Genomics. 2005; 15(6):415-21.
34. Wu JS, Buettner C, Smithline H, Ngo LH, Greenman RL. Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications. Muscle Nerve. 2011; 43(1): 76-81.
35. Yu JG, Sewright K, Hubal MJ, et al. Investigation of gene expression in C(2)C(12) myotubes following simvastatin application and mechanical strain. J. Atheroscler. Thromb. 2009; 16(1):21-9.